A clonal derivative of a transfectant of the SP2/0 myeloma cell line producing a chimeric monoclonal antibody was maintained in steady-state, continuous culture at dilution rates ranging from 0.21 to 1.04 day-'. The steady-state values for nonviable and total cell concentrations increased as the dil
Safety aspects in the quality control of recombinant products from mammalian cell culture
β Scribed by Robert L. Garnick
- Publisher
- Elsevier Science
- Year
- 1989
- Tongue
- English
- Weight
- 720 KB
- Volume
- 7
- Category
- Article
- ISSN
- 0731-7085
No coin nor oath required. For personal study only.
β¦ Synopsis
The recent approval of the recombinant DNA-derived biological, human tissue-type plasminogen activator (rt-PA), obtained from large scale mammalian cell culture, addressed a number of issues concerning the safety of recombinant products. The assurance of the safety of such highly complex proteins requires that the following topics be investigated: the characterisation of the recombinant production organism; control of large scale cell culture production conditions; design of the purification process and consistency of manufacture; the purity, safety, and stability testing of the final product; and clinical studies. Each of the topics described above is discussed with respect to those key quality control issues that ensure the safety of the product. The use of analytical techniques such as peptide mapping and multiantigen ELISA assays to guarantee both the genetic stability and the purity of the final product is also discussed.
π SIMILAR VOLUMES
Arsenobetaine, arsenocholine, trimethylarsine oxide and tetramethylarsonium iodide, which are contained in marine fishery products, were examined for their potencies on cell growth inhibition, chromosomal aberration and sister chromatid exchange (SCE). Arsenobetaine, the major water-soluble organic
## Abstract There are a growing number of reports on the subβphysiological temperature culturing (<37Β°C) of mammalian cells for increased recombinant protein yield, although the effect is variable between cell lines, expression systems, and the product of interest. What is becoming clear is that ex
## Abstract Biopharmaceuticals represent significant advances in therapeutic approaches for unmet medical needs, and increasingly, traditional pharmaceutical firms have been incorporating biotechnology capabilities into their product portfolios. There are some differences in the overall safety test